RecruitingNot ApplicableNCT07383363

Comparison of Efficacy and Safety of Vita 6 Versus Zinc Along With Applied Behavioural Therapy

Comparison of Efficacy and Safety of Vita 6 Versus Zinc Along With Applied Behavioural Therapy in Management of Autism Spectrum Disorder in Children Aged 3-14 Years


Sponsor

Muhammad Aamir Latif

Enrollment

64 participants

Start Date

Sep 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The study seeks to fill the gaps in available local data regarding the diagnosis and its management, as multiple treatments are in practice. Therefore, the study aimed at the comparison of efficacy and safety of Vita 6 versus zinc along with applied behavioral therapy in the management of autism spectrum disorder in children aged 3-14 years.


Eligibility

Min Age: 3 YearsMax Age: 12 Years

Inclusion Criteria4

  • Children of any gender
  • Aged 3-12 years
  • Newly diagnosed patients of autism spectrum disorder following the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
  • Not taking any treatment

Exclusion Criteria2

  • With any of psychiatric disorder
  • With any of movement disorder

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVita 6

Patients will be given one tablet of Vita 6 (50 mg) twice a day for 3 months, along with applied behavioral therapy.

DRUGZinc sulfate

Patients will receive syrup zinc sulfate 2 mg/kg/day as a single dose for 3 months, along with applied behavioral therapy.


Locations(1)

Children Hospital and Institute of Child Health

Multan, Punjab Province, Pakistan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07383363


Related Trials